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Factors determining hemoglobin carbamylation in renal failure. Car-
bamylated hemoglobin (carhb) is formed by the reaction of hemoglobin
with cyanate, a product of in vivo urea dissociation. It is found in high
levels in patients with renal failure and may be useful in their clinical
evaluation. Accordingly, we measured carhb by HPLC after acid hydroly-
sis in 73 patients with renal failure and 11 controls. Mean carhb levels,
(expressed as .tg valine hydantoin/g Hb), were highest in chronic renal
failure (CRF, 146 13), intermediate in end-stage renal disease on
hemodialysis (ESRD, 106 7), and lowest in acute renal failure (ARF, 80
12) when compared to normal subjects (27 2). In all patients carhb
was significantly correlated with BUN but not with creatinine, bicarbon-
ate, or phosphate. For any level of BUN above 80 mgldl, carhb was
substantially higher in CRF than in ARF. Predialysis BUN and urea
reduction ratio (URR) were significant predictors of carhb in ESRD. To
investigate the effect of time of exposure and BUN level on the rate of
carbamylation of hemoglobin, blood from normal subjects and dialysis
patients was incubated in vitro with urea equivalent to BUN levels of 50,
100, 150, and 200 mgldl and assayed for carhb at 0,5, 9, and 14 days. Carhb
increased linearly over the first nine days of urea exposure and leveled off
thereafter. The rate of carbamylation increased as BUN increased and was
significantly higher in hemoglobin from dialysis patients than from normal
subjects. These results show that the higher the level of carhb at baseline,
the higher the rate of carbamylation upon exposure to increasing urea
concentrations. We conclude that carhb formation is dependent on urea
concentration and length of exposure to urea. The rate of carhb formation
for a given urea concentration is greater in hemoglobin already carbamy-
lated, and this may explain why carhb is higher in CRF than in ARF at
BUN levels greater than 80 mgldl. Carhb may thus be a useful index of the
duration and degree of exposure to high blood urea levels in patients with
renal failure, and may potentially serve as an index of the adequacy of
dialysis.
Urea is retained in renal failure along with other metabolites
and serves the clinician as a marker of nitrogen retention. It
spontaneously rearranges under physiologic conditions to form
ammonia and cyanate [1]. The protonated form of cyanate,
isocyanic acid, reacts with the a and amino groups of proteins
resulting in the carbamylation of proteins [2]. Carbamylation of
amino acids, plasma proteins, leukocyte proteins, and hemoglobin
have all been shown to occur in renal failure [3—14]. The amino
terminal valine of hemoglobin is particularly reactive with isocya-
nate, forming a stable modified hemoglobin termed carbamylated
hemoglobin (carhb) [2, 15, 16]. Each a amino valine of the four
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hemoglobin chains comprising a hemoglobin molecule may theo-
retically be altered by this reaction.
The pharmacologic carbamylation of hemoglobin by cyanate
has been extensively studied and appears to proceed by the
binding of cyanate to an anion binding site involving the Val-1 and
Arg-141 of the a chain prior to the proton transfer that results in
carbamylation [17]. The a chains of hemoglobin are known to
carbamylate twice as fast in the deoxy compared to the oxy state
[15]. The carbamylation of hemoglobin S is known to result in
inhibition of sickling and enhancement of oxygen affinity [2, 16,
18—20]. These findings suggest that the carbamylation of individ-
ual hemoglobin chains result in conformational changes that alter
the biochemical behavior of hemoglobin.
The acid hydrolysis of carhb results in the formation of valine
hydantoin from the modified amino terminal valine. Its quantita-
tion by gas chromatography [3, 4, 211 or high performance liquid
chromatography (HPLC) [6] is a measure of carhb levels. Al-
though carhb levels have been correlated with blood urea nitrogen
(BUN) in patients with renal failure, including those on dialysis or
post-renal transplantation [3, 4, 7], the kinetics of hemoglobin
carbamylation in renal failure are largely unknown. Of particular
interest is the relationship of carhb levels to increasing urea
concentrations over time and the rate of the urea accumulation. It
is also not known if the alterations in bicarbonate and phosphate
concentrations found in renal failure may influence hemoglobin
carbamylation independently of urea concentration.
To answer these questions, we measured carhb in patients with
renal failure of varying duration (ARF vs. CRF) and in ESRD
patients on hemodialysis. We sought to determine the relationship
of carhb levels with urea concentration, length of urea exposure,
rate of urea increase, and anion (bicarbonate, phosphate) con-
centrations by both in vivo and in vitro studies. Our findings
suggest that carhb may be a good index of chronic urea exposure
in renal failure in a manner analogous to glycosylated hemoglobin
in monitoring glycemic exposure in diabetics.
Methods
Patients
The patients with ARF or CRF were selected from those
referred to the renal service as either inpatients or outpatients;
those with ESRD came from an outpatient dialysis unit, and
medical staff volunteers served as healthy controls. Patients
without prior blood laboratory data or with recent blood transfu-
sions (within 2 months) were excluded. ARF was documented
based on clinical assessment and increasing BUN and creatinine
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Table 1. Characteristics of normal subjects and patients
Group Normal ARF CRF ESRD
Number 11 10 32 31
Ageyears 30 5 48 9 52 15 54 2
Range 24—39 36—64 32—94 25—76
Male/Female 9/2 8/2 23/9 20/11
Underlying nephropathy
DM 12 6
HTN 12 14
HIV 2 1
ATN 8
Prerenal 1
Obstruction 1
Nephrotic 1 3
Polycystic 1
Myeloma 1
IgA 1
Unknown 8 6
from known normal baselines extending back for an eight week
period at most. CRF was documented based on clinical assess-
ment and elevated BUN and creatinine over at least a six month
period. Patients with ESRD had been on standard hemodialysis
using cellulose acetate dialyzers for at least three months and had
not received blood transfusions within the prior two months. The
urea reduction ratio (URR) for each patient was calculated by
dividing the difference between pre- and post-dialysis BUN by the
pre-BUN. Table 1 summarizes the clinical characteristics of all
patients and normal subjects studied.
Measurements
Blood samples of approximately 5 ml were obtained in hepa-
rinized monoject tubes (Sherwood Co., St. Louis, MO, USA).
Plasma BUN, creatinine, bicarbonate, and phosphate were mea-
sured by the Kodak Ectachem 700XR C Series Analyzer, and
hemoglobin was determined by the Coulter/STKS model 807.
The determination of carbamylated hemoglobin by HPLC was
based on the method of Kwan et al [7}. A 0.5 ml aliquot from each
blood sample was washed twice by gently mixing it with 5 ml of
isotonic saline, followed by centrifugation at 3000 X g for five
minutes and removal of the supernatant. If hemolysis was evident
by the presence of pink supernatant, the aliquot was replaced by
another from the same sample. Washed erythrocytes were used
immediately or stored at —20°C not longer than two weeks until
further processing.
Valine hydantoin (VH) was extracted after hydrolysis of hemo-
globin by the following procedure. One ml of HC1 (11 mol/liter)
and acetic acid (17 mol/liter) were added to each aliquot of
washed erythrocytes and heated for two hours at 110°C. After
allowing the hydolysate to cool for 15 minutes, 2 ml of 10 M NaOH
was added and incubated for 10 minutes at room temperature.
One hundred microliters of N-Carbamyl-D,L-Norvaline (CNV) at
96 mg/liter was added as an internal standard and after adding 5
ml of ethyl acetate each sample was vortexed. The ethyl acetate
extracts the VH and the CNV from the aqueous phase. Samples
were centrifuged at 3000 X g for 10 minutes and 4.5 ml of the
supernatant was transferred into another tube and vortexed with
2 ml of NaFICO3 followed by centrifugation at 3000 X g for five
minutes. Four ml of the supernatant was then transferred into a
glass tube and dried completely under an air stream at 70°C.
Dried samples were reconstituted in 0.5 ml of the mobile phase
(6% acetonitrile in deionized water, pH adjusted with acetic acid
to 4.0) and heated at 70°C for five minutes. Twenty microliters of
the reconstituted sample were injected into a Beckman Liquid
Chromatograph Model 336 fitted with a nonheated C18 reverse
phase column (5 p, 4.5 x 250 mm, Jones Chromatography,
Littleton, CO, USA). Injected samples were eluted with the
mobile phase using the Beckman delivery system Model 11OB at
a flow rate of 1.5 ml/min. The column effluent was monitored by
a variable wavelength detector (Beckman Model 163) at 210 nm.
Under these conditions, VH and CNV eluted at approximate
retention times of 8.5 and 10.2 minutes.
Each HPLC run included a standard sample consisting of 100
ii N-Carbamyl-D,L-Valine (32 mg/liter) that underwent the same
process as the washed erythrocytes. Carbamylated hemoglobin
was calculated by dividing the ratio of the VH and CNV peak
height for the patient sample by the same ratio for the standard
sample, multiplying by 3.2 g, and dividing by 0.5 ml and the
hemoglobin concentration (g/100 ml).
Each carhb value is representative of a single aliquot for the
majority of patients. Preliminary experiments using replicate
aliquots indicated an interassay coefficient of variation of 5.6% for
normal carhb (20 to 40) and 4.0% for high carhb levels (> 100).
All chemicals and HPLC grade solvents were purchased from
Sigma except the acetonitrile (Fisher).
In vitro study
To determine the relationship of urea concentration and time
of urea exposure to the carbamylation rate of hemoglobin, blood
samples from five normal subjects and four ESRD patients were
collected in heparinized Monoject tubes. Post-dialysis blood sam-
ples were obtained from the ESRD patients. For each individual,
1 ml aliquots of fresh whole blood in glass tubes were exposed to
different urea concentrations (100, 200, 300, 400 mg/dl) by the
addition of urea to each aliquot. Although the blood was handled
carefully to avoid bacterial contamination, the experiment was
conducted under non-sterile conditions. The sealed glass tubes
containing the aliquots were kept in an incubator without agita-
tion at 37°C for 0, 5, 9, and 14 days. No clotting of blood was
observed due to the presence of heparin. Aliquots without added
urea were incubated for the same number of days to serve as a
time control. At the end of the indicated time periods, the aliquots
were processed for the determination of carhb starting at the acid
hydrolysis step. Hemoglobin concentration of the blood samples
were determined at the start of the experiment and these values
were used for the subsequent calculation of carhb at each data
point.
To determine if elevated glycosylated hemoglobin (ghb) inter-
feres with carbamylation, blood from diabetics with normal renal
function were obtained and 1 ml aliquots were incubated in 200
mg/dl urea at 37°C for five days. Carhb was measured at 0 and five
days and the increase in carhb was compared between diabetics
with normal glycosylated hemoglobin (7.8 0.3%, N = 4) and
elevated glycosylated hemoglobin (14.7 0.6%, N = 4). Baseline
(0 days) carhb (33.3 4.3 vs. 25.8 3.4 jg VH/g Hb), BUN (15.5
2.6 vs. 11.3 2 mgldl), and hemoglobin (12.7 0.8 vs. 12.6
0.2 g/dl) were not different between the two groups of diabetics.
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Table 2. Laboratory findings among normal subjects and patient groups
Lab data Normal ARF CRF ESRD
BUN mg/dl 12 1 126 27 90 6 79 4
Creat mgldl 0.9 0 7.2 1.1 8.9 0.8 14.1 0.7a
Bicarb mEqiliter 18.2 1.0 20.2 1.0 18.9 0.6
Phos mg/dl 8.1 0.9a 5.5 0.3 5.5 0.2
Hgbg/dl 15.1 0.6 10.4 0.8 10 0.4 9.5 0.2
URR 0.56 0.01
Carhb 27 2 80 12 146 13 106 7
a Denotes values that are significantly different when compared among
patient groups by ANOVA
Table 3. Multiple regression analysis to identify predictors of carhb in
renal failure
Group
Regression equationY = Carhb
r
value
P
value
ARF Y = —37 + .7>< BUN + 3.2 x
CREAT + 3 x BICARB -
PHOS
4.9 x
0.97 <0.05
N = 10
CRF Y = —8.4 + 1.5 x BUN + 5.9x
CREAT + 1.8 x BICARB
PHOS
- 13.2 x
0.64 <0.01
N = 22
ESRD Y = 104 + 1.3 x BUN — 3.8 x
BICARB — 5.2 x PHOS
0.65 <0.01
N = 29
P values refer to the entire equation. BUN was the only significant (P <
0.05) predictor of carhb in each equation. Only patients in each group who
had complete sets of lab data were included.
Fig. 1. Carhb in ARF, CRF, ESRD, and normal subjects. Differences
amongst groups were statistically significant by ANOVA.
Statistics
Data are presented as means standard error. Comparisons
between groups were done by analysis of variance. Multiple linear
regression analyses were done using Minitab statistical software.
A P value < 0.05 was considered statistically significant.
Results
The baseline laboratory data for patients and normal subjects
are shown in Table 2. Mean BUN was highest in ARF (126 27
mg/dl, N = 10), intermediate in CRF (90 6, N = 32), and lowest
in ESRD on hemodialysis (79 4, N = 31). Carhb levels were
significantly different among the groups: lowest in ARF (80 12
VH/g Hb), intermediate in ESRD (106 7), and highest in
CRF (146 13; Table 2, Fig. 1). Multiple regression analysis for
each patient group showed that carhb was significantly correlated
with BUN but not with creatinine, bicarbonate, or phosphate
(Table 3). For ESRD a separate regression analysis showed that
both pre-dialysis BUN (preBUN) and URR were significant
individual predictors of carhb levels. However, the best prediction
of carhb was attained when the two variables were combined into
a multiple regression analysis (Table 4). In both CRF and ESRD
patients, carhb levels were not significantly correlated with age in
the range of 29 to 94 years. In CRF patients, carhb was 136 + 0.18
x age (N = 30, r = 0.03, NS); in ESRD patients, carhb was 71.8
+ 0.64 X age (N = 31, r = 0,20, NS). Because erythropoietin has
been suggested to affect carhb levels, we analyzed the relationship
between carhb levels and the dose of erythropoietin in 28 of 32
ESRD patients who were receiving erythropoietin and found no
Table 4. Regression analysis for predicting carhb in ESRD patients
(N = 30)
Regression equationY = Carhb
r
value
P
value
Y 39.4 + 0.86 >< preBUN 0.39 <0.03
Y = 208 — 1.82 x URR 0.40 <0.03
Y = 137 — 1.56 >< URR + 0.73 X preBUN 0.52 <0.02
P values refer to the entire equation. In the bottom equation URR and
preBUN were not significant predictors of carhb individually.
correlation with the dose of erythropoietin given per dialysis
treatment (mean 4855 383 units).
To determine whether diabetes mellitus affects carhb levels, we
divided the patients with CRF into diabetics and non-diabetics. At
comparable levels of BUN (diabetics, BUN 93 8, N = 12;
non-diabetics, BUN 89 12 mgldl, N = 19) carhb levels were not
different (diabetics, 148.4 13.4 vs. non-diabetics, 141.5 21 g
VH/g Hb, NS). A similar conclusion was reached when the data of
ESRD patients were analyzed (data not shown). The in vitro
experiment using blood from diabetics showed that high levels of
glycosylated hemoglobin did not interfere with hemoglobin car-
bamylation. No significant difference was found in the absolute
increase in carhb between patients with normal versus elevated
glycosylated hemoglobin (70.4 11.2, N = 4 vs. 89.3 10.5 g
VH/g Hb, N = 4, NS).
The strength of the correlation of carhb with BUN is graphically
illustrated in Figure 2, which shows carhb in CRF and ARF
patients plotted against BUN. The data for CRF patients best fit
an exponential curve (y = 35.977e°°135', r = 0.76); the data for
ARF patients are best fitted by a simple linear regression (y =
0.343x + 36.469, r = 0.79). Clear separation between the two
groups was apparent at BUN levels > 80 mg/dl.
In an attempt to delineate the factors responsible for the higher
carhb in CRF patients we reviewed the laboratory data within the
four months prior to blood sampling. Assuming a linear rise in
BUN, the rate of change in BUN was calculated by dividing the
difference in BUN over time in weeks. CRF patients with a rising
BUN (>2.0 mgldl/week) and ARF patients were compared.
Figure 3B shows a plot of carhb versus the rate of rise in BUN for
ARF patients. The Figure 3A shows the CRF patients subdivided
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nine days, we divided the amount of carhb increase from baseline
by the number of days at each sampling interval and plotted the
values against urea nitrogen concentration and took this value to
represent the rate of carbamylation. Figure 5 shows the rate of
carbamylation per day plotted against urea nitrogen for hemoglo-
bin from normal subjects and from ESRD patients. As the urea
nitrogen was increased, the rate of increase in the amount of
carhb over the nine days period (expressed as the rate of carhb
formation per day in j.g valine hydantoin/g Hb/day) was signifi-
cantly greater for hemoglobin from ESRD patients versus normal
subjects. The slopes were significantly different by analysis of
variance (9.3 vs. 4.5 respectively, P < 0.01), showing that hemo-
globin of ESRD patients had a greater carbamylation rate than
that of normal subjects at all levels of urea concentrations. These
results show that length of exposure to elevated urea concentra-
tion and prior carbamylation are important in determining carhb
levels.
Discussion
Carbamylated hemoglobin is produced by the reaction of
cyanate with the N-terminal valine of hemoglobin. Earlier studies
using animals injected with '4C-labeled cyanate [22] and the
experience with carbamylation of hemoglobin S with sodium
cyanate [2, 15, 161 clearly substantiates this origin of carhb. The
few studies that have attempted to measure plasma cyanate in
humans have shown very low levels [23], most likely because of its
high reactivity, particularly with sulfhydryl and amino groups. The
strong correlation between carhb and BUN levels would support
the view that cyanate formed by the spontaneous rearrangement
of urea is the source of carbamylated hemoglobin. This is also
rendered plausible by the known highly reactive nature of cyanate
with the a amino group of Val-1 of the globin chain [17].
We have shown that BUN is linearly related to carhb in acute
renal failure, whereas in chronic renal failure the relationship
becomes exponential. In CRF patients with BUN levels > 80
mg/dl, the influence of urea exposure time appears to be a more
important determinant of carhb levels than in ARF. Moreover,
among the CRF patients, as BUN levels increased over 2 mg/dl/
week during the prior three to four months, carhb levels progres-
sively rose. Although the assumption of a linear increase in BUN
over time may not be completely accurate, carhb levels were
clearly highest in CRF patients with an increasing BUN. It would
appear then that the carbamylation rate may be determined not
only by mean blood urea concentration and length of exposure,
but also by other factors intrinsic to worsening CRF.
Our in vitro data confirm that carbamylation rate in hemoglobin
from ESRD patients at comparable levels of urea nitrogen was
significantly higher than that of normal subjects. Despite the
inherent limitations of this in vitro study to reflect the precise
biochemical conditions in vivo, the results are consistent with our
clinical observations. Accordingly, ARF patients have a much
smaller degree of hemoglobin carbamylation than CRF patients,
and CRF patients manifest an exponential rise in hemoglobin
carbamylation as BUN increases.
The observed difference between the carbamylation rate in
ARF versus CRF may be accounted for by several factors. It could
be that carbamylation is increased in a hemoglobin molecule that
is already carbamylated because of certain conformational
changes. N-terminal sites are known to be important in maintain-
ing the quaternaly structure of hemoglobin. They participate in
0 50 100 150 200 250 300 350
BUN, mg/dI
Fig. 2. Carhb plotted against BUN level in patients with ARE ) andGRE().
into two groups: those who had a stable BUN and those who had
a rise in BUN > 2 mg/dl/week. It is clear that the patients with the
rising BUN have greater levels of carhb than those with a stable
BUN. In patients with CRF a small rise in BUN was associated
with a much greater level of carhb as compared to ARF, suggest-
ing that the time of exposure to urea is an important determinant
of the carhb level.
To determine if the cumulative exposure to urea is an important
independent determinant of hemoglobin carbamylation, we cal-
culated the total amount of urea exposure over a period of time
("chronic urea nitrogen load") by measuring the BUN over two
time points and multiplying the average BUN by time. This
approach avoids the assumption made above, that the rise in BUN
was linear per week and provides an estimate of the "urea load"
to which the RBCs were exposed. Multiple regression analysis
yielded the following equations for predicting carhb using initial
BUN and the chronic urea nitrogen load (CUNL) in CRF and
ARF patients with two values of BUN over at most a four months
span. In CRF patients, carhb = 29.8 + 1.15 x BUN + 0.87 x
CUNL (N = 18), r = 0.63, P < 0.02 while in ARF patients, carhb
= 39 + 0.58 x BUN — 0.19 X CUNL (N = 7), r = 0.82, P <0.06.
It is apparent from the larger coefficient (0.87 vs. —0.19) in CRF
patients that for this group of patients chronic urea nitrogen load
was a more important factor in determining carhb levels.
These results suggest that the rate of carbamylation is greater in
CRF patients in whom the BUN is increasing as compared to
ARF patients in whom by definition BUN is rising rapidly. This
implies that rate of rise in BUN by itself is not the only important
factor in determining carbamylation rate in renal failure. In vitro
experiments were conducted to confirm under more controlled
conditions whether the carbamylation rate for hemoglobin from
patients with ESRD was greater than that of normal subjects with
comparable urea concentrations and time of urea exposure.
Figure 4 shows the relationship of carhb plotted against time at
different levels of urea nitrogen concentration in vitro. Carhb
levels increase as urea nitrogen concentrations increase and at all
levels of urea nitrogen the carhb levels plateau after nine days of
exposure. Because the amount of carhb increased linearly over
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Fig. 4. In vitro carbamylation of hemoglobin from normal subjects (A) and
ESRD patients (B) under conditions of increasing urea nitrogen concentra-
tion (mg/dl) and time (days). Baseline carhb for normal Day 0 = 34 4 jg
VH/g Hb, N = 5. Normal subjects had an age range of 28 to 39, mean
32.2 2.6 Baseline carhb for ESRD Day 0 = 129 29, N = 4. ESRD
patients had an age range of 22 to 46, mean = 35.3 5.8. Diagnoses
included diabetes mellitus (2) and focal segmental glomerulosclerosis (2).
Symbols are: () Day 0; (U) Day 5; (D) Day 9; (U) Day 14.
the hydrogen bonding that alters the conformation of the protein
as it changes from a deoxy to an oxy conformation. The carbamy-
lation of an individual globin chain, by altering the overall confor-
mation of the hemoglobin tetramer, may facilitate carbamylation
of the subsequent chain. The enhanced oxygen affinity of car-
bamylated hemoglobin [15] and the greater carbamylation rate of
deoxyhemoglobin [15, 17] support this hypothesis. This could
explain why in CRF patients the carhb rises exponentially as BUN
30
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Fig. 3. Carhb plotted against the increase in
BUN/week (mg/dl/week). A. CRF patients with() increasing BUN [175] and stable BUN (U).
B. ARF patients [117].
rises. Less likely, plasma factors may have enhanced the sponta-
neous rearrangement of urea to cyanate or the binding of cyanate
to the N-terminal valine of hemoglobin. Another possibility would
be that anions such as bicarbonate and phosphate would compete
with cyanate for its binding site on hemoglobin [17]. The low
bicarbonate concentration in renal failure would enhance car-
bamylation whereas the high phosphate might inhibit it. However,
this explanation is not borne out by our studies, which showed that
carhb levels were not influenced by these anions.
Our findings support the potential value of carhb as a marker of
chronic urea exposure, because its formation rate is determined
by mean blood urea concentration and length of urea exposure.
The significant correlation of carhb with predialysis BUN and
urea reduction ratio in ESRD hemodialysis patients would suggest
a role as an indicator of time averaged urea exposure, particularly
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Fig. 5. The carbamylation rate over the first nine days of in vitro urea
exposure of hemoglobin from normal subjects (•) and CREpatients (LI).
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in patients who receive inadequate dialysis due to noncompliance
and poor access. Further work is needed to determine if carhb
levels truly reflect chronic urea exposure when monitored longi-
tudinally in hemodialysis patients and if elevated levels correlate
with increased morbidity and mortality.
Reprint requests to James Stim, M.D., Division of Nephrology, Department
of Medicine Cook County Hospital, 215 Durand, 1835 West Harrison Street,
Chicago, illinois 60612, USA.
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